Psoriasis is a multifactorial immune-mediated disease characterized by systemic inflammation and immune dysfunction. It manifests as itchy, scaly plaques that significantly impair the quality of life and mental well-being of patients, and these lesions commonly appear on the knees, elbows, trunk, and scalp. Current therapeutic approaches aim to slow excessive skin cell growth and alleviate symptoms, and they include topical treatments, phototherapy, and systemic therapies such as immunosuppressants and biologics. Recent guidelines from the American Academy of Dermatology and the National Psoriasis Foundation (AAD/NPF) recommend biologics as a first-line treatment for moderate-to-severe plaque psoriasis, given their high specificity, efficacy, and safety (JAMA, 2020; 323(19):1945-1960). Biologics have consequently become a focal point in psoriasis drug development.
As a preclinical CRO specializing in non-human primate (NHP) pharmacology research, Prisys Biotech develops clinically relevant large-animal disease models. Its capabilities integrate in vivo pharmacology, in vitro analytical testing, and advanced pathological assessments. That combination is what made the Cynomolgus Monkey Psoriasis Model possible, and it is also what makes the model usable once a sponsor has a candidate to test.
Building The Cynomolgus Monkey Psoriasis Model
Prisys Biotech employs the widely recognized imiquimod (IMQ)-induced method. By administering a precise dose of IMQ to healthy cynomolgus monkeys, the team mimics the pathological changes observed in human psoriasis. Studies are run in three groups: a normal control group, an IMQ-induced model group, and a treatment group receiving calcitriol.
Following IMQ induction, the model and treatment groups exhibited distinct psoriasis-like lesions. Calcitriol treatment in the positive drug group significantly ameliorated these skin abnormalities, and clinical scoring across all groups revealed significant differences, which is the readout that separates a model that forms lesions from one that responds to a drug known to work in patients.
- Psoriasis Assessment*
Pathological Insights And Clinical Relevance
To further investigate the progression of psoriasis, skin samples were collected at multiple stages: pre-induction, induction, post-induction, treatment, and post-treatment. Histological analyses revealed hallmark psoriasis features in the model and treatment groups, including inflammatory cell infiltration, parakeratosis, and hyperkeratosis.
Sampling at each of those stages is what lets a sponsor separate an effect on lesion formation from an effect on established lesions. Symptoms in the treatment group improved substantially after calcitriol administration, and the histopathology corroborates the clinical scores. That pairing of a clinical readout with a tissue readout is what a sponsor needs when a candidate has to be defended to a regulator.
- Histopathology findings: After IMQ topical application for 21 days *
- and daivobet treatment for 7 days: decrease thickness of epithelium (stratum spinosum), *
- reduce inflammatory cell infiltration underneath epidermis, reduce scaling,*
What The Model Supports In Preclinical Development
The cynomolgus monkey psoriasis model replicates the key pathological features of human psoriasis, which makes it a platform for preclinical drug screening and therapeutic research. It connects experimental findings with clinical application, because lesion formation, epidermal turnover, and drug response can be read in a species whose skin and immune system sit closer to the human case. Sponsors use a model of this kind to rank candidates, to choose a dose before toxicology, and to decide whether a mechanism is worth a clinical program.
About Prisys Biotech
Prisys Biotech provides preclinical research services with a focus on non-human primate models, and develops disease-specific models for Immunology & Inflammation, CNS disorders, hematological diseases, and dermatology. Its real-time imaging platforms, advanced pathology capabilities, and AI-driven behavioral analysis systems support studies from model induction through endpoint analysis, and the Translational-Research-Center page describes the facility behind them.
